Valeant Pharmaceuticals CEO J. Michael Pearson took down more than $10 million last year, including a whopping $8 million in incentive pay. But the real surprises in the company's 2015 proxy statement are farther down the chart.
Pfizer spinoff Zoetis, the animal health company, added a second director to its board under a deal it reached earlier this year with activist investor Bill Ackman and his firm Pershing Square Capital Management.
Blend Therapeutics, which was founded by Omid Farokhzad and MIT's Robert Langer, has named Drew Fromkin as its new CEO.
Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or...
The head of India's National Pharmaceutical Pricing Authority was removed from the job just a week after his agency allowed the prices of 509 essential drugs to increase by 3.8%. But Chairman Injeta Srinivas' removal more likely was the result of complaints from the pharma and devices industries, which objected to recent moves he made that cost them money.
Pfizer has a new vaccines R&D head in Kathrin Jansen, who will begin at the post on June 1. Previously CSO of Pfizer's vaccine research and early development, Jansen will report to global R&D president Mikael Dolsten and work out of Pfizer's Pearl River, New York research site.
Seunghee Kim, a veteran member of South Korea's Ministry of Food and Drug Safety, has been named to become its first female minister. Kim has a pharmacology degree from Seoul National University and a doctorate in biochemistry from Notre Dame.
CRISPR Therapeutics--which was founded in Switzerland by Emmanuelle Charpentier, one of the pioneers in the field--has hired Alexion vet Bill Lundberg to head up its R&D operations in Cambridge, MA.
Marijn Dekker's time in the Bayer CEO chair is winding down, and the Dutchman has a couple of big items left on his to-do list before he turns over the reins. But thanks to his penchant for risk-taking, in the 5-plus years he's been with the German pharma, he's gotten plenty done already.
The head of Cipla's India operations has resigned from his post just more than a year after joining from GlaxoSmithKline in January last year, the company said in an email to FiercePharmaAsia.